Search Results

Your search matched 102 results

#1

How Patient Advocacy Connectivity Fuels Launch Success | Perspectives

Keri McDonough, our communications and advocacy relations strategist, lays out our top 10 recommendations for meaningful patient advocacy group engagement on the runway to launch and beyond.

#2

Patient Advocacy Transparency Act and the Growing Call for Disclosure | Blog

As anticipated, on June 6, 2018, Senator Claire McCaskill (D-Mo.) introduced the Patient Advocacy Transparency Act.

#3

The Syneos Health Podcast: Advocacy Archetypes | Perspectives

Patient advocacy has evolved over time, and with it, patient advocate archetypes have emerged.

#4

BETTER TOGETHER: STRENGTHENING ADVOCACY-INDUSTRY PARTNERSHIPS | Perspectives

Since the fall of 2015, and against a backdrop of harsh media attention to pharmaceutical pricing, patient advocacy groups that form partnerships with pharma companies have received negative coverage in The New York Times, USA Today and other publications.

#5

August 2018: How Patient Advocacy Connectivity Fuels Launch Success | Newsletters

Keri McDonough, one of our patient advocacy specialists, provides ten recommendations on how to meaningfully engage with patient advocacy groups throughout the lifecycle of a product.

#6

What Patient Advocacy Groups Want | Blog

And, turns out, it’s what patient advocacy groups want from pharma, too.

#7

Expect more transparency around pharma's advocacy group partnerships in 2019 | In The Media

In 2018, pharma-advocacy partnerships made headlines for their incredible work but also caught heat over payments.

#8

Patient Advocacy at the Center of Patient-Centered Design | Blog

Representatives from small and big pharma, and those fighting both rare diseases and more prevalent ones, came together in San Diego recently for WIB-Southern California: The Growing Importance of Patient Advocacy in BioPharma.

#9

AN ADVOCACY RX FOR PROGRESS IN MENTAL HEALTH | Perspectives

As a source of human suffering, a barrier to workplace productivity, a burden on families and a driver of medical costs, mental illness amounts to an unparalleled public health crisis.

#10

Advocacy in HIV: Applying Blood Pressure | Blog

Live From Lions Health: Nearly 2/3s of the world’s developed countries have a ban on gay and bisexual men donating blood.

#11

SHARING THE MISSION TO CONQUER RARE DISEASES | Perspectives

At an ever-quickening pace, biopharmaceutical companies and patient advocacy groups are banding together to hasten development of new drugs for rare diseases.

#12

Rare Disease and the Powerful Role of Patient Centricity | Blog

Collaboration between advocacy groups and the healthcare industry can lead to better treatments, more engaged relationships and better quality of care.

#13

Opening a New Era in Rare Disease Medicines | In The Media

Jeanine O'Kane and Marie Emms, senior executives at Syneos Health, address rare disease pricing and the ties between manufacturers, payers and patient advocacy groups.

#14

Patient Advisory Boards Deliver Focused and Fruitful Insights, but Only When That’s Really the Goal | Perspectives

In this guest blog, Keri Mcdonough, Lead, Advocacy and Patient Relations at Syneos Health Communications shares her insight on how to assemble a patient advisory board that accurately and effectively represents the patient voice.

#15

As Precision Medicine Grows, so Does the Importance of Clinical Trial Diversity | In The Media

Keri McDonough, Patient Advocacy Lead at Syneos Health Communications, was featured in MedCity News discussing how CROs can highlight the practical and socioeconomic barriers to greater trial diversity.

#16

Modern Activism in Healthcare: A Guide for Preventing Your Advocates from Becoming Activists | Perspectives

Our PR Group is just back from Strengthening Patient Advocacy Relations Conference where Meg Alexander, Head, Reputation & Risk Management & Chris Iafolla, Head, Digital & Social Strategy, presented “Worlds Colliding: When Patient Activism Meets Pharma’s Digital Channels".

#17

THE NEW PARTNERSHIP PARADIGM: WHAT PATIENT ADVOCATES SEEK FROM PHARMACEUTICAL PARTNERS | Perspectives

Dramatic changes in U.S. healthcare over the last few years have forced a rethinking of the partnerships pharmaceutical companies form with groups representing patients and families.

#18

In Patient Advocacy,“Grassroots” Means Meeting People Face to Face | In The Media

Learn about why it's still important to consider a human approach in healthcare communications from Jeanine O'Kane, President, Public Relations Group at inVentiv Health Communications.

#19

Syneos Health Communications Adds New Talent in Europe, Enhancing Medical Affairs Expertise | In The Media

Syneos Health Communications – the portfolio of Syneos Health® agencies designed to deliver insights-driven integrated communications spanning advertising, public relations, patient advocacy, medical communications

#20

2nd Annual Strategic Internal Communications for Health Care | In The Media

Alex Ferrara, Director, Corporate Communications, INC Research/inVentiv Health is presenting on the topic "How To Activate Employees As Advocates On Social And Digital Channels" at the Strategic Internal Communications for Health Care conference on September 13th.

#21

Top Patient and Advocate Quotes for Pharma from eyeforpharma ‘18 | Blog

Live from EFP ‘18: This afternoon, a panel of 5 patients, advocates and pharma-patient connectors engaged in a discussion titled, “Where is the trust?

#22

A new approach to fighting drug shortages | Blog

Shortages of critical cancer-fighting drugs have impacted 83% of U.S. oncologists in the past six months.* Around the world, doctors are negotiating availability, access and funding for the infusions they most want to prescribe.

#23

The Syneos Health Podcast: Talking about PIE | Perspectives

PIE – or Preapproval Information Exchange – refers to the communication of clinical and health care economic information on therapies in development between U.S. population health decision makers and drug manufacturers prior to regulatory approval.

#24

Patient-Finding Approaches for Rare Disease | Blog

Mark Baglin, Vice President of Global Marketing at Alnylam Pharmaceuticals, works in ultra ultra rare diseases, like Hereditary ATTR Amyloidosis.

#25

Consumer Brands are Challenging Traditional Practices | Blog

I’ve been frustrated with the process of buying glasses for some time now.

#26

Chandler Chicco Agency | Agency

Global PR agency pioneering health communications programs that engage key stakeholders throughout the product lifecycle

#27

Betting Big on Cancer.com | Blog

This month, Janssen launched Cancer.com, aiming to create an online destination for all things oncology.

#28

What Biogen’s Alzheimer’s Drug Approval Means for Life Sciences Companies | Blog

In a highly anticipated decision, the Food and Drug Administration (FDA) last week cleared Alzheimer’s disease drug aducanumab on an accelerated, conditional approval program.

#29

Five Recent Developments Radically Re-Shaping New Drug Commercialization | Perspectives

In just the past five years, significant changes have occurred in how new drugs come to market.

#30

What Do You Get When You Combine Scientists and Patients? | Blog

This summer, students in California Institute for Regenerative Medicine’s Bridges to Stem Cell Research and Therapy program at California State University (CSU) San Marcos had new lab partners: families impacted by rare diseases.